Key Events This Week
11 May: Technical downgrade to Sell amid bearish momentum
14 May: Intraday high of Rs.4,990 with an 8.19% surge
15 May: Week closes at Rs.4,854.50 (+1.71%) outperforming Sensex
May 20
BSE+NSE Vol: 1.76 k
Sanofi Consumer Healthcare India Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved technical outlook and positive financial trends. The company’s robust quarterly results, strong management efficiency, and net-debt-free status have contributed to this reassessment, despite some concerns over valuation and long-term growth. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced the recent rating change.
Read full news article
11 May: Technical downgrade to Sell amid bearish momentum
14 May: Intraday high of Rs.4,990 with an 8.19% surge
15 May: Week closes at Rs.4,854.50 (+1.71%) outperforming Sensex
The Sensex advanced 1.05% on 14 May 2026, yet Sanofi Consumer Healthcare India Ltd outpaced the broader market with an 8.19% gain, reaching an intraday high of Rs 4990. This 6.14-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector’s 2.36% rise signals a distinctly stock-specific rally rather than a mere market tailwind.
Read full news articleSanofi Consumer Healthcare India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 11 May 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 13 May 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news articleSanofi Consumer Healthcare India Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a complex market sentiment for this small-cap pharmaceutical player.
Read full news articleSanofi Consumer Healthcare India Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a nuanced market sentiment. Recent technical indicators reveal a blend of bullish and neutral signals, suggesting cautious optimism among investors in the Pharmaceuticals & Biotechnology sector.
Read full news articleSanofi Consumer Healthcare India Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite a recent downgrade in daily moving averages and a 3.05% decline in the stock price, certain weekly indicators suggest pockets of bullishness, reflecting a complex technical landscape for this pharmaceuticals and biotechnology small-cap.
Read full news articleSanofi Consumer Healthcare India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 May 2026. While the rating was revised on this date, the analysis below reflects the stock's current fundamentals, returns, and financial metrics as of 02 May 2026, providing investors with an up-to-date perspective on the company’s standing.
Read full news articleThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Nippon India Mutual Fund
Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed.
The Board of Directors at its meeting held on Tuesday 28th April 2026 considered and approved the Unaudited Financial Results for the quarter ended 31st March 2026. In this regard please find enclosed a press release.
No Upcoming Board Meetings
Sanofi Consumer Healthcare India Ltd has declared 550% dividend, ex-date: 17 Apr 25
No Splits history available
No Bonus history available
No Rights history available